메뉴 건너뛰기




Volumn 63, Issue 8, 2014, Pages 1325-1332

HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis b: Clinical outcomes and durability

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

EID: 84904042319     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-305517     Document Type: Article
Times cited : (319)

References (50)
  • 1
    • 33748114343 scopus 로고    scopus 로고
    • The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
    • DOI 10.1016/j.jhep.2006.05.013, PII S0168827806002972
    • Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-38. (Pubitemid 44307383)
    • (2006) Journal of Hepatology , vol.45 , Issue.4 , pp. 529-538
    • Perz, J.F.1    Armstrong, G.L.2    Farrington, L.A.3    Hutin, Y.J.F.4    Bell, B.P.5
  • 2
    • 33748306328 scopus 로고    scopus 로고
    • Prevention of mortality from hepatitis B and hepatitis C
    • DOI 10.1016/S0140-6736(06)69347-1, PII S0140673606693471
    • Schiff ER. Prevention of mortality from hepatitis B and hepatitis C. Lancet 2006;368:896-7. (Pubitemid 44331366)
    • (2006) Lancet , vol.368 , Issue.9539 , pp. 896-897
    • Schiff, E.R.1
  • 3
    • 0025753470 scopus 로고
    • Incidence, determinants and significance of delayed clearance of serum HBs AG in chronic hepatitis b virus infection: A prospective study
    • Liaw YF, Sheen IS, Chen TJ, et al. Incidence, determinants and significance of delayed clearance of serum HBs AG in chronic hepatitis B virus infection: A prospective study. Hepatology 1991;13:627-31.
    • (1991) Hepatology , vol.13 , pp. 627-631
    • Liaw, Y.F.1    Sheen, I.S.2    Chen, T.J.3
  • 4
    • 72949113706 scopus 로고    scopus 로고
    • Loss of HBs AG antigen during treatment with entecavir or lamivudine in nucleoside-naive HBEAG-positive patients with chronic hepatitis b
    • Gish RG, Chang TT, Lai CL, et al. Loss of HBs AG antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat 2010;17:16-22.
    • (2010) J Viral Hepat , vol.17 , pp. 16-22
    • Gish, R.G.1    Chang, T.T.2    Lai, C.L.3
  • 5
    • 75449107726 scopus 로고    scopus 로고
    • Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B
    • Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422-30.
    • (2010) Hepatology , vol.51 , pp. 422-430
    • Chang, T.T.1    Lai, C.L.2    Kew, Y.S.3
  • 6
    • 84865487986 scopus 로고    scopus 로고
    • Sustained responses and loss of HBs AG in HBEAG-negative patients with chronic hepatitis b who stop long- Term treatment with adefovir
    • Hadziyannis SJ, Sevastianos V, Rapti I, et al. Sustained responses and loss of HBs AG in HBeAg-negative patients with chronic hepatitis B who stop long- Term treatment with adefovir. Gastroenterology 2012;143:629-36.
    • (2012) Gastroenterology , vol.143 , pp. 629-636
    • Hadziyannis, S.J.1    Sevastianos, V.2    Rapti, I.3
  • 7
    • 84873726484 scopus 로고    scopus 로고
    • Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study
    • Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study. Lancet 2013;381:468-75.
    • (2013) Lancet , vol.381 , pp. 468-475
    • Marcellin, P.1    Gane, E.2    Buti, M.3
  • 8
    • 48549107919 scopus 로고    scopus 로고
    • Sustained HBEAG and HBs AG loss after long- Term follow-up of HBEAG-positive patients treated with peginterferon alpha-2b
    • Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBs AG loss after long- Term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008;135:459-67.
    • (2008) Gastroenterology , vol.135 , pp. 459-467
    • Buster, E.H.1    Flink, H.J.2    Cakaloglu, Y.3
  • 9
    • 67349168493 scopus 로고    scopus 로고
    • High rates of HBs AG seroconversion in HBEAG-positive chronic hepatitis B patients responding to interferon: A long- Term follow-up study
    • Moucari R, Korevaar A, Lada O, et al. High rates of HBs AG seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: A long- Term follow-up study. J Hepatol 2009;50:1084-92.
    • (2009) J Hepatol , vol.50 , pp. 1084-1092
    • Moucari, R.1    Korevaar, A.2    Lada, O.3
  • 11
    • 34248679355 scopus 로고    scopus 로고
    • HBs AG seroclearance in asymptomatic carriers of high endemic areas: Appreciably high rates during a long- Term follow-up
    • Chu CM, Liaw YF. HBs AG seroclearance in asymptomatic carriers of high endemic areas: Appreciably high rates during a long- Term follow-up. Hepatology 2007;45:1187-92.
    • (2007) Hepatology , vol.45 , pp. 1187-1192
    • Chu, C.M.1    Liaw, Y.F.2
  • 12
    • 53049107213 scopus 로고    scopus 로고
    • HBs AG seroclearance in chronic hepatitis B in Asian patients: Replicative level and risk of hepatocellular carcinoma
    • Yuen MF, Wong DK, Fung J, et al. HBs AG Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008;135:1192-9.
    • (2008) Gastroenterology , vol.135 , pp. 1192-1199
    • Yuen, M.F.1    Wong, D.K.2    Fung, J.3
  • 13
    • 70349240414 scopus 로고    scopus 로고
    • Chronic hepatitis B: Update 2009
    • Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2.
    • (2009) Hepatology , vol.50 , pp. 661-662
    • Lok, A.S.1    McMahon, B.J.2
  • 14
    • 84862664371 scopus 로고    scopus 로고
    • EASL clinical practice guidelines: Management of chronic hepatitis b virus infection
    • European Association for the Study of the Liver
    • European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-85.
    • (2012) J Hepatol , vol.57 , pp. 167-185
  • 15
    • 33847028842 scopus 로고    scopus 로고
    • Identification of a hepatitis B virus S gene mutant in lamivudine- Treated patients experiencing HBs AG seroclearance
    • Hsu CW, Yeh CT, Chang ML, et al. Identification of a hepatitis B virus S gene mutant in lamivudine- Treated patients experiencing HBs AG seroclearance. Gastroenterology 2007;132:543-50.
    • (2007) Gastroenterology , vol.132 , pp. 543-550
    • Hsu, C.W.1    Yeh, C.T.2    Chang, M.L.3
  • 17
    • 27744494442 scopus 로고    scopus 로고
    • Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea
    • Bae SH, Yoon SK, Jang JW, et al. Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea. J Korean Med Sci 2005;20:816-20.
    • (2005) J Korean Med Sci , vol.20 , pp. 816-820
    • Bae, S.H.1    Yoon, S.K.2    Jang, J.W.3
  • 20
    • 0142244873 scopus 로고    scopus 로고
    • Determinants for sustained HBEAG response to lamivudine therapy
    • Chien RN, Yeh CT, Tsai SL, et al. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003;38:1267-73.
    • (2003) Hepatology , vol.38 , pp. 1267-1273
    • Chien, R.N.1    Yeh, C.T.2    Tsai, S.L.3
  • 21
    • 4644219526 scopus 로고    scopus 로고
    • Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma
    • DOI 10.1136/gut.2003.033324
    • Chan HL, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004;53:1494-8. (Pubitemid 39265273)
    • (2004) Gut , vol.53 , Issue.10 , pp. 1494-1498
    • Chan, H.L.-Y.1    Hui, A.Y.2    Wong, M.L.3    Tse, A.M.-L.4    Hung, L.C.-T.5    Wong, V.W.-S.6    Sung, J.J.-Y.7
  • 22
    • 51049117284 scopus 로고    scopus 로고
    • Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma
    • Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008;100:1134-43.
    • (2008) J Natl Cancer Inst , vol.100 , pp. 1134-1143
    • Yang, H.I.1    Yeh, S.H.2    Chen, P.J.3
  • 23
    • 13844322073 scopus 로고    scopus 로고
    • Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: A prospective study in men
    • Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: A prospective study in men. J Natl Cancer Inst 2005;97:265-72.
    • (2005) J Natl Cancer Inst , vol.97 , pp. 265-272
    • Yu, M.W.1    Yeh, S.H.2    Chen, P.J.3
  • 24
    • 30944449596 scopus 로고    scopus 로고
    • Long- Term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis b
    • Arase Y, Ikeda K, Suzuki F, et al. Long- Term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 2006;119:71.9-16.
    • (2006) Am J Med , vol.119 , Issue.71 , pp. 9-16
    • Arase, Y.1    Ikeda, K.2    Suzuki, F.3
  • 25
    • 0036789020 scopus 로고    scopus 로고
    • Prognosis following spontaneous HBs AG seroclearance in chronic hepatitis b patients with or without concurrent infection
    • Chen YC, Sheen IS, Chu CM, et al. Prognosis following spontaneous HBs AG seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002;123:1084-9.
    • (2002) Gastroenterology , vol.123 , pp. 1084-1089
    • Chen, Y.C.1    Sheen, I.S.2    Chu, C.M.3
  • 26
    • 77953441846 scopus 로고    scopus 로고
    • Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy
    • Yeh CT. Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy. Antivir Ther 2010;15:471-5.
    • (2010) Antivir Ther , vol.15 , pp. 471-475
    • Yeh, C.T.1
  • 27
    • 0033754947 scopus 로고    scopus 로고
    • Evolution of hepatitis B virus polymerase gene mutations in hepatitis b e antigen-negative patients receiving lamivudine therapy
    • Lok AS, Hussain M, Cursano C, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000;32:1145-53.
    • (2000) Hepatology , vol.32 , pp. 1145-1153
    • Lok, A.S.1    Hussain, M.2    Cursano, C.3
  • 28
    • 0036038911 scopus 로고    scopus 로고
    • Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene
    • DOI 10.1006/viro.2002.1448
    • Torresi J, Earnest-Silveira L, Civitico G, et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 2002;299:88-99. (Pubitemid 35007514)
    • (2002) Virology , vol.299 , Issue.1 , pp. 88-99
    • Torresi, J.1    Earnest-Silveira, L.2    Civitico, G.3    Walters, T.E.4    Lewin, S.R.5    Fyfe, J.6    Locarnini, S.A.7    Manns, M.8    Trautwein, C.9    Bock, T.C.10
  • 29
    • 33745619248 scopus 로고    scopus 로고
    • Hepatitis B virus mutations associated with antiviral therapy
    • Bartholomeusz A, Locarnini S. Hepatitis B virus mutations associated with antiviral therapy. J Med Virol 2006;78(Suppl 1):52-5.
    • (2006) J Med Virol , vol.78 , Issue.SUPPL. 1 , pp. 52-55
    • Bartholomeusz, A.1    Locarnini, S.2
  • 30
    • 0242487671 scopus 로고    scopus 로고
    • Identification of a novel pre-S2 mutation in a subgroup of chronic carriers with spontaneous clearance of hepatitis B virus surface antigen
    • Yeh CT, Chang MH, Lai HY, et al. Identification of a novel pre-S2 mutation in a subgroup of chronic carriers with spontaneous clearance of hepatitis B virus surface antigen. J Gastroenterol Hepatol 2003;18:1129-38.
    • (2003) J Gastroenterol Hepatol , vol.18 , pp. 1129-1138
    • Yeh, C.T.1    Chang, M.H.2    Lai, H.Y.3
  • 31
    • 47249117068 scopus 로고    scopus 로고
    • Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant
    • Sloan RD, Ijaz S, Moore PL, et al. Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant. Antivir Ther 2008;13:439-47. (Pubitemid 352016737)
    • (2008) Antiviral Therapy , vol.13 , Issue.3 , pp. 439-447
    • Sloan, R.D.1    Ijaz, S.2    Moore, P.L.3    Harrison, T.J.4    Teo, C.-G.5    Tedder, R.S.6
  • 32
    • 77950969605 scopus 로고    scopus 로고
    • Comparison of the technical and clinical performance of the elecsys HBs AG II assay with the architect, Ax Sym, and advia centaur HB SAG screening assays
    • Louisirirotchanakul S, Khupulsup K, Akraekthalin S, et al. Comparison of the technical and clinical performance of the Elecsys HBs AG II assay with the Architect, AxSym, and Advia Centaur HBs AG screening assays. J Med Virol 2010;82:755-62.
    • (2010) J Med Virol , vol.82 , pp. 755-762
    • Louisirirotchanakul, S.1    Khupulsup, K.2    Akraekthalin, S.3
  • 34
    • 84555209282 scopus 로고    scopus 로고
    • Prevalence of and risk factors for hepatitis B viremia after spontaneous hepatitis b surface antigen seroclearance in hepatitis B carriers
    • Chu CM, Liaw YF. Prevalence of and risk factors for hepatitis B viremia after spontaneous hepatitis B surface antigen seroclearance in hepatitis B carriers. Clin Infect Dis 2012;54:88-90.
    • (2012) Clin Infect Dis , vol.54 , pp. 88-90
    • Chu, C.M.1    Liaw, Y.F.2
  • 35
    • 79960124298 scopus 로고    scopus 로고
    • Serum HBs AG decline during long- Term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBs AG loss
    • Zoutendijk R, Hansen BE, van Vuuren AJ, et al. Serum HBs AG decline during long- Term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBs AG loss. J Infect Dis 2011;204:415-18.
    • (2011) J Infect Dis , vol.204 , pp. 415-418
    • Zoutendijk, R.1    Hansen, B.E.2    Van Vuuren, A.J.3
  • 36
    • 80054724912 scopus 로고    scopus 로고
    • Hepatitis B surface antigen quantification: Why and how to use it in 2011- A core group report
    • Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011- A core group report. J Hepatol 2011;55:1121-31.
    • (2011) J Hepatol , vol.55 , pp. 1121-1131
    • Chan, H.L.1    Thompson, A.2    Martinot-Peignoux, M.3
  • 37
    • 84866705034 scopus 로고    scopus 로고
    • Restored function of HBV-specific T cells after long- Term effective therapy with nucleos(t)ide analogues
    • Boni C, Laccabue D, Lampertico P, et al. Restored function of HBV-specific T cells after long- Term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012;143:963-73.
    • (2012) Gastroenterology , vol.143 , pp. 963-973
    • Boni, C.1    Laccabue, D.2    Lampertico, P.3
  • 39
    • 80052957789 scopus 로고    scopus 로고
    • Hepatitis b surface antigen (HBs AG) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBs AG loss during treatment with nucleoside/nucleotide analogues
    • Jaroszewicz J, Ho H, Markova A, et al. Hepatitis B surface antigen (HBs AG) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBs AG loss during treatment with nucleoside/nucleotide analogues. Antivir Ther 2011;16:915-24.
    • (2011) Antivir Ther , vol.16 , pp. 915-924
    • Jaroszewicz, J.1    Ho, H.2    Markova, A.3
  • 40
    • 78650477355 scopus 로고    scopus 로고
    • Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B
    • Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132-43.
    • (2011) Gastroenterology , vol.140 , pp. 132-143
    • Heathcote, E.J.1    Marcellin, P.2    Buti, M.3
  • 41
    • 84883212438 scopus 로고    scopus 로고
    • Reduction of hepatitis b surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy
    • Seto WK, Wong DK, Fung J, et al. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology 2013;58:923-31.
    • (2013) Hepatology , vol.58 , pp. 923-931
    • Seto, W.K.1    Wong, D.K.2    Fung, J.3
  • 42
    • 84904063753 scopus 로고    scopus 로고
    • Seroclearance rate of hepatitis b surface antigen in 2, 112 patients with chronic hepatitis in Japan during long- Term follow-up
    • Epub ahead of print
    • Kobayashi M, Hosaka T, Suzuki F, et al. Seroclearance rate of hepatitis B surface antigen in 2, 112 patients with chronic hepatitis in Japan during long- Term follow-up. J Gastroenterol 2013:Epub ahead of print.
    • (2013) J Gastroenterol
    • Kobayashi, M.1    Hosaka, T.2    Suzuki, F.3
  • 43
    • 84861185904 scopus 로고    scopus 로고
    • HBV DNA suppression and HBs AG clearance in HBEAG negative chronic hepatitis B patients on lamivudine therapy for over 5 years
    • Fasano M, Lampertico P, Marzano A, et al. HBV DNA suppression and HBs AG clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. J Hepatol 2012;56:1254-8.
    • (2012) J Hepatol , vol.56 , pp. 1254-1258
    • Fasano, M.1    Lampertico, P.2    Marzano, A.3
  • 44
    • 77956592924 scopus 로고    scopus 로고
    • Kinetics of hepatitis b surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients
    • Wursthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010;52:1611-20.
    • (2010) Hepatology , vol.52 , pp. 1611-1620
    • Wursthorn, K.1    Jung, M.2    Riva, A.3
  • 45
    • 65449123444 scopus 로고    scopus 로고
    • Early serum HBs AG drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBEAG-negative patients
    • Moucari R, Mackiewicz V, Lada O, et al. Early serum HBs AG drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151-7.
    • (2009) Hepatology , vol.49 , pp. 1151-1157
    • Moucari, R.1    Mackiewicz, V.2    Lada, O.3
  • 46
    • 83455163799 scopus 로고    scopus 로고
    • Prediction of off- Treatment response to lamivudine by serum hepatitis b surface antigen quantification in hepatitis B e antigen-negative patients
    • Chan HL, Wong GL, Chim AM, et al. Prediction of off- Treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients. Antivir Ther 2011;16:1249-57.
    • (2011) Antivir Ther , vol.16 , pp. 1249-1257
    • Chan, H.L.1    Wong, G.L.2    Chim, A.M.3
  • 47
    • 84876286013 scopus 로고    scopus 로고
    • A predictive scoring system for the seroclearance of HBs AG in HBEAG-seronegative chronic hepatitis B patients with genotype b or c infection
    • Liu J, Lee MH, Batrla-Utermann R, et al. A predictive scoring system for the seroclearance of HBs AG in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol 2013;58:853-60.
    • (2013) J Hepatol , vol.58 , pp. 853-860
    • Liu, J.1    Lee, M.H.2    Batrla-Utermann, R.3
  • 48
    • 84865535075 scopus 로고    scopus 로고
    • A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis b surface antigen seroclearance
    • Seto WK, Wong DK, Fung J, et al. A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. Hepatology 2012;56:812-19.
    • (2012) Hepatology , vol.56 , pp. 812-819
    • Seto, W.K.1    Wong, D.K.2    Fung, J.3
  • 49
    • 84984571825 scopus 로고    scopus 로고
    • Determinants of spontaneous surface antigen loss in hepatitis b e antigen-negative patients with a low viral load
    • Tseng TC, Liu CJ, Yang HC, et al. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology 2011;55:68-76.
    • (2011) Hepatology , vol.55 , pp. 68-76
    • Tseng, T.C.1    Liu, C.J.2    Yang, H.C.3
  • 50
    • 84880939335 scopus 로고    scopus 로고
    • Long- Term hepatitis b surface antigen (HBs AG) kinetics during nucleoside/nucleotide analogue therapy: Finite treatment duration unlikely
    • Chevaliez S, Hezode C, Bahrami S, et al. Long- Term hepatitis B surface antigen (HBs AG) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol 2013;58:676-83.
    • (2013) J Hepatol , vol.58 , pp. 676-683
    • Chevaliez, S.1    Hezode, C.2    Bahrami, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.